IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
This ta ble shows the com pany’s lead ing ten phar ma ceu ti cal prod ucts. For each prod uct, its per cent age
share of cor po rate rev e nue and US dol lar and US dol lar fixed rate growth are shown. In this study, in ter -
na tional prod ucts are used. The con cept of the in ter na tional prod uct was de vised for IMS’s in ter na tional
da ta base MI DAS, to en able us ers to eval u ate sales of a prod uct in ter na tion ally, even if the prod uct is
known by dif fer ent names in dif fer ent coun tries. Prod ucts are linked in ter na tion ally if at least two of the
fol low ing three char ac ter is tics are the same as in coun try of first launch: brand name; marketing
corporation; active ingredients.
The top ten in ter na tional prod ucts ac counted for 44.4% of cor po rate rev e nue.
Pharmaceutical Sales Analysis By Product Age
US
Dollar
Sales
(‘000s)
Share of
Worldwide
Corporate Sales
%
Percentage
Growth Sep
07/Sep 08
USD USD FIXED
RATE
TOTAL SALES 36296737 100.0 8 1
PRODS 1-2 YEARS 2969278 8.2 194 184
PRODS 3-5 YEARS 4524839 12.5 13 5
PRODS 6-10 YEARS 12086224 33.3 3 -3
PRODS 11 YEARS 16716396 46.1 -2 -7
This ta ble an a lyzes com pany sales by prod uct age, as sess ing sales in terms of new prod ucts, es tab lished
prod ucts, ma ture prod ucts and old prod ucts. A new prod uct is de fined as a new launch of an ex ist ing
prod uct, a new chem i cal en tity or a com bi na tion prod uct in an in di vid ual coun try over the last two years
to September 2008.
© 2009 IMS Health In cor po rated or its af fil i ates Page 121